NASDAQ:MLND Millendo Therapeutics (MLND) Stock Price, News & Analysis → The most important AI company you've never heard of (From Manward Press) (Ad) Free MLND Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.35▼$3.5850-Day Range$3.06▼$5.8452-Week Range$0.92▼$16.95Volume329,490 shsAverage Volume1.52 million shsMarket Capitalization$64.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Millendo Therapeutics alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Millendo Therapeutics Stock (NASDAQ:MLND)As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. MLND Stock News HeadlinesMarch 20, 2024 | msn.comA lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about accessMarch 7, 2024 | msn.comMind Medicine sends psychedelic stocks higher after FDA status for LSD formulationJanuary 11, 2024 | markets.businessinsider.comClearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private PlacementDecember 5, 2023 | msn.comWhy Is Clearmind Medicine (CMND) Stock Up 50% Today?November 6, 2023 | markets.businessinsider.comMaxim Group Maintains Their Buy Rating on Mind Medicine (MMED)March 15, 2023 | benzinga.comExpert Ratings for Decibel TherapeuticsDecember 29, 2022 | insidermonkey.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Call TranscriptDecember 29, 2022 | yahoo.comClearmind Medicine Announces Shareholders Meeting ResultsJune 3, 2022 | finance.yahoo.comClearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in IndiaMay 31, 2022 | finance.yahoo.comDTx Pharma Appoints Michael Huang, MD as Chief Medical OfficerMay 19, 2022 | finance.yahoo.comClearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol ConsumptionMay 16, 2022 | seekingalpha.comMind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call TranscriptMay 15, 2022 | finance.yahoo.comClearmind Announces Pre-IND Meeting Date with FDASee More Headlines Receive MLND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Millendo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MLND CUSIPN/A CIKN/A Webwww.millendo.com Phone734 845 9000FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-91.03% Return on Assets-72.44% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book1.91Miscellaneous Outstanding Shares19,043,000Free FloatN/AMarket Cap$64.75 million OptionableNot Optionable Beta0.48 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key CompetitorsAileron TherapeuticsNASDAQ:ALRNMural OncologyNASDAQ:MURAViveon Health AcquisitionNYSE:VHAQLantern PharmaNASDAQ:LTRNAEON BiopharmaNASDAQ:AEONView All Competitors MLND Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Millendo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bionano Genomics (BNGO), DURECT (DRRX), Geron (GERN) and Heat Biologics (HTBX). This page (NASDAQ:MLND) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
